Pulmatrix, Inc. (PULM) |
|
2.92 0.08 (2.82%)
|
03-31 15:59 |
|
Open: |
2.877 |
Pre. Close: |
2.84 |
|
High:
|
3.04 |
Low:
|
2.86 |
|
Volume:
|
5,313 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:21:30 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 3.87 One year: 4.27 |
| Support: |
Support1: 2.76 Support2: 2.3 |
| Resistance: |
Resistance1: 3.31 Resistance2: 3.65 |
| Pivot: |
3.03  |
| Moving Average: |
MA(5): 2.92 MA(20): 3.12
MA(100): 3.63 MA(250): 4.2 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 14.1 %D(3): 12 |
| RSI: |
RSI(14): 35.1 |
| 52-week: |
High: 7.5 Low: 2.76 |
| Average Vol(K): |
3-Month: 24 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PULM ] has closed above bottom band by 27.8%. Bollinger Bands are 48% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.04 - 3.06 |
3.06 - 3.08 |
|
Low:
|
2.82 - 2.84 |
2.84 - 2.86 |
|
Close:
|
2.92 - 2.95 |
2.95 - 2.98 |
|
Company Description |
|
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. |
Headline News |
Thu, 30 Mar 2023
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and ... - PR Newswire
Mon, 06 Feb 2023
Pulmatrix Announces First Patient Dosed in Phase 2b Study of ... - PR Newswire
Mon, 23 Jan 2023
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology - Yahoo Finance
Wed, 04 Jan 2023
Pulmatrix Announces Positive Top Line Results from a Phase 1 ... - PR Newswire
Thu, 22 Sep 2022
Pre-market Movers: PRST, KOD, GRVY, BEAT, PULM… - Nasdaq
Mon, 08 Aug 2022
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
4 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
19.6 (%) |
|
Shares Short
|
45 (K) |
|
Shares Short P.Month
|
42 (K) |
Stock Financials |
|
EPS
|
-0.68 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-4.14 |
|
EPS Est Next Year
|
-4.49 |
|
Book Value (p.s.)
|
0.63 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-387.4 |
|
Return on Assets (ttm)
|
-22.9 |
|
Return on Equity (ttm)
|
-46.5 |
|
Qtrly Rev. Growth
|
75 |
|
Gross Profit (p.s.)
|
1.42 |
|
Sales Per Share
|
1.32 |
|
EBITDA (p.s.)
|
-5.09 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-4.39 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.6 |
|
Price to Sales
|
2.22 |
|
Price to Cash Flow
|
-0.58 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-02-05 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
